Our latest Diabetes Drug Insights study follows a group of more than n=3,000 people with type 2 diabetes in the USA from 2018 to 2024.
Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.
Despite clear evidence that hormonal fluctuations during menstruation impact blood glucose, these effects are often overlooked in diabetes care.
